Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2018 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, Nov 10, 2017
Slide 1: Alkem Laboratories Ltd. Investor Presentation Q2FY18
Alkem Laboratories Ltd. Investor Presentation Q2FY18 10th November 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights For The Quarter
Key Highlights For The Quarter Robust quarter – Strong revenue growth accompanied with improved EBITDA margins • Strong growth in the India Business: • Strong bounce back in Q2FY18 following a week Q1FY18 performance helped by channel filling post the GST roll-out • Company’s mega brands continued t
Slide 4: Key Financial Highlights - Q2FY18 (Consolidated)
Key Financial Highlights - Q2FY18 (Consolidated) All figures in Rs mn Total Revenue from Operations India sales 14,056 Adjusting for the 18,649 12,258 impact of GST, YoY growth was higher 16,383 Q2FY17 Q2FY18 International sales 4,385 3,892 Q2FY17 Q2FY18 Notes: Post implementation of GST with effect
Slide 5: Key Financial Highlights - Q2FY18 (Consolidated)
Key Financial Highlights - Q2FY18 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 4,605 11,569 9,970 3,105 60.9% 62.0% 19.0% 24.7% Q2FY17 Q2FY18 Q2FY17 Q2FY18 PBT (before Minority Interest) PAT (after Minority Interest) 3,207 4,321 2,828 3,069 Q2FY17 Q2FY18
Slide 6: Key Financial Highlights - H1FY18 (Consolidated)
Key Financial Highlights - H1FY18 (Consolidated) Particulars (Rs mn) H1FY18 H1FY17 YoY growth Revenue from Operations 31,602 31,192 1.3% YoY performance in H1FY18 was Gross Profit 18,897 18,989 -0.5% mainly impacted by significant level of destocking that took place in the Gross Profit margin 59.8%
Slide 7: India Business
India Business India Business: Q2FY18 Sales of Rs.14,056 million (14.7% growth YoY) • India sales contributed 76.2% to total sales in Q2FY18 • YoY growth during the quarter was helped by post-GST channel filling • The Company maintained its leading positions in its established therapy areas of Anti-
Slide 8: US Business
US Business US Business: Q2FY18 Sales of Rs.3,042 million (0.6% growth YoY) • US sales contributed 16.5% to total sales in Q2FY18 • YoY growth during the quarter was partly impacted by adverse currency movement • In Q2FY18, the Company filed 4 ANDAs with the US FDA and received 3 final approvals • A
Slide 9: Other International Business
Other International Business Other International Business: Q2FY18 Sales of Rs.1,342 million (54.5% growth YoY) • Other International Market sales contributed 7.3% to total sales in Q2FY18 • Company’s key markets including Australia, Philippines, Chile and Kazakhstan recorded healthy growth • YoY gro
Slide 10: Consistent Strategy, Strong Execution
Consistent Strategy, Strong Execution 1 India Sales: Consolidate Company’s leadership position in the acute segment by driving growth in its mega brands 2 India Sales: Increase Company’s market share in the chronic segment through market share acquisition and new product introductions 3 Improve fiel
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 30th September 2017 Non-Institution, 26.58% Promoter & Institution, Promoter Group, 6.40% 67.02% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 12: Thank You
Thank You